APA (7th ed.) Citation

Hughes, B., Mileshkin, L., Townley, P., Gitlitz, B., Eaton, K., Mitchell, P., . . . Pirzkall, A. (2011). 9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes. European Journal of Cancer, 47, S629. https://doi.org/10.1016/S0959-8049(11)72431-5

Chicago Style (17th ed.) Citation

Hughes, B., et al. "9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes." European Journal of Cancer 47 (2011): S629. https://doi.org/10.1016/S0959-8049(11)72431-5.

MLA (9th ed.) Citation

Hughes, B., et al. "9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes." European Journal of Cancer, vol. 47, 2011, p. S629, https://doi.org/10.1016/S0959-8049(11)72431-5.